The combination of ezetimibe and ursodiol promotes fecal sterol excretion and reveals a G5G8-independent pathway for cholesterol elimination

Yuhuan Wang, Xiaoxi Liu, Sonja S. Pijut, Jianing Li, Jamie Horn, Emily Bradford, Markos Leggas, Terrence A. Barrett, Gregory A. Graf

Journal of Lipid Research · 2015 · 18 citations · 33 references

DOIFull text

Open access

Concepts

Abstract

Previous studies suggest an interdependent relationship between liver and intestine for cholesterol elimination from the body. We hypothesized that a combination of ursodiol (Urso) and ezetimibe (EZ) could increase biliary secretion and reduce cholesterol reabsorption, respectively, to promote cholesterol excretion. Treatment with Urso increased hepatic ABCG5 ABCG8 (G5G8) protein and both biliary and fecal sterols in a dose-dependent manner. To determine whether the drug combination (Urso-EZ) further increased cholesterol excretion, mice were treated with Urso alone or in combination with two doses of EZ. EZ produced an additive and dose-dependent increase in fecal neutral sterol (FNS) elimination in the presence of Urso. Finally, we sequentially treated wide-type and G5G8-deficient mice with Urso and Urso-EZ to determine the extent to which these effects were G5G8 dependent. Although biliary and FNS were invariably lower in G5G8 KO mice, the relative increase in FNS following treatment with Urso alone or the Urso-EZ combination was not affected by genotype. In conclusion, Urso increases G5G8, biliary cholesterol secretion, and FNS and acts additively with EZ to promote fecal sterol excretion. However, the stimulatory effect of these agents was not G5G8 dependent. Previous studies suggest an interdependent relationship between liver and intestine for cholesterol elimination from the body. We hypothesized that a combination of ursodiol (Urso) and ezetimibe (EZ) could increase biliary secretion and reduce cholesterol reabsorption, respectively, to promote cholesterol excretion. Treatment with Urso increased hepatic ABCG5 ABCG8 (G5G8) protein and both biliary and fecal sterols in a dose-dependent manner. To determine whether the drug combination (Urso-EZ) further increased cholesterol excretion, mice were treated with Urso alone or in combination with two doses of EZ. EZ produced an additive and dose-dependent increase in fecal neutral sterol (FNS) elimination in the presence of Urso. Finally, we sequentially treated wide-type and G5G8-deficient mice with Urso and Urso-EZ to determine the extent to which these effects were G5G8 dependent. Although biliary and FNS were invariably lower in G5G8 KO mice, the relative increase in FNS following treatment with Urso alone or the Urso-EZ combination was not affected by genotype. In conclusion, Urso increases G5G8, biliary cholesterol secretion, and FNS and acts additively with EZ to promote fecal sterol excretion. However, the stimulatory effect of these agents was not G5G8 dependent. Elevated cholesterol is an important risk factor for cardiovascular disease, and strategies to promote cholesterol elimination have long been used to reduce the risk of atherosclerosis. An emerging body of literature suggests that cholesterol also plays an active role in the development of nonalcoholic fatty liver disease (NAFLD) and its progression to nonalcoholic steatohepatitis (NASH). Adding cholesterol to a high-fat (HF) diet in C57BL/6J mice leads to significantly more profound hepatosteatosis, inflammation, and fibrosis resembling human NASH (1Savard C. Tartaglione E.V. Kuver R. Haigh W.G. Farrell G.C. Subramanian S. Chait A. Yeh M.M. Quinn L.S. Ioannou G.N. Synergistic interaction of dietary cholesterol and dietary fat in inducing experimental steatohepatitis.Hepatology. 2013; 57: 81-92Crossref PubMed Scopus (191) Google Scholar). Similarly, in LDL receptor-deficient mice, adding cholesterol to an HF, high-sucrose diet exacerbates the development of insulin resistance and steatosis resulting in NASH (2Subramanian S. Goodspeed L. Wang S. Kim J. Zeng L. Ioannou G.N. Haigh W.G. Yeh M.M. Kowdley K.V. O'Brien K.D. et al.Dietary cholesterol exacerbates hepatic steatosis and inflammation in obese LDL receptor-deficient mice.J. Lipid Res. 2011; 52: 1626-1635Abstract Full Text Full Text PDF PubMed Scopus (173) Google Scholar). In a mouse model of Alström syndrome, an elevation in hepatic free cholesterol due to an increase in hepatic uptake and a decrease in biliary elimination is thought to play a contributing role in the development of liver disease (3Van Rooyen D.M. Larter C.Z. Haigh W.G. Yeh M.M. Ioannou G. Kuver R. Lee S.P. Teoh N.C. Farrell G.C. Hepatic free cholesterol accumulates in obese, diabetic mice and causes non-alcoholic steatohepatitis.Gastroenterology. 2011; 141: 1393-1403.e5Abstract Full Text Full Text PDF PubMed Scopus (237) Google Scholar). Strategies that promote hepatic cholesterol elimination are likely to have therapeutic benefit in NAFLD. The ABCG5 ABCG8 (G5G8) heterodimer is the primary mediator of hepatobiliary elimination, accounting for 70% to 90% of biliary cholesterol secretion (4Sabeva N.S. Liu J. Graf G.A. The ABCG5 ABCG8 sterol transporter and phytosterols: implications for cardiometabolic disease.Curr. Opin. Endocrinol. Diabetes Obes. 2009; 16: 172-177Crossref PubMed Scopus (35) Google Scholar). In addition, it also opposes phytosterol absorption in the proximal small intestine (4Sabeva N.S. Liu J. Graf G.A. The ABCG5 ABCG8 sterol transporter and phytosterols: implications for cardiometabolic disease.Curr. Opin. Endocrinol. Diabetes Obes. 2009; 16: 172-177Crossref PubMed Scopus (35) Google Scholar, 5Berge K.E. Tian H. Graf G.A. Yu L. Grishin N.V. Schultz J. Kwiterovich P. Shan B. Barnes R. Hobbs H.H. Accumulation of dietary cholesterol in sitosterolemia caused by mutations in adjacent ABC transporters.Science. 2000; 290: 1771-1775Crossref PubMed Scopus (1348) Google Scholar). We previously reported that G5G8 plays an essential role in the development of diet-induced obesity phenotypes independent of its role in opposing phytosterol accumulation. The absence of G5G8 and reduced biliary cholesterol secretion resulted in hepatic cholesterol accumulation, acceleration of obesity and insulin resistance, and worsening of NAFLD in mice challenged with a plant sterol-free (PSF) HF diet (6Su K. Sabeva N.S. Liu J. Wang Y. Bhatnagar S. van der Westhuyzen D.R. Graf G.A. The ABCG5 ABCG8 sterol transporter opposes the development of fatty liver disease and loss of glycemic control independently of phytosterol accumulation.J. Biol. Chem. 2012; 287: 28564-28575Abstract Full Text Full Text PDF PubMed Scopus (40) Google Scholar). Conversely, increasing biliary cholesterol secretion by adenoviral expression of G5G8 restored glycemic control, improved hepatic insulin signaling, and lowered plasma TGs in genetically obese, db/db mice (7Su K. Sabeva N.S. Wang Y. Liu X. Lester J.D. Liu J. Liang S. Graf G.A. Acceleration of biliary cholesterol secretion restores glycemic control and alleviates hypertriglyceridemia in obese db/db mice.Arterioscler. Thromb. Vasc. Biol. 2014; 34: 26-33Crossref PubMed Scopus (16) Google Scholar). Increased biliary and fecal sterol elimination following adenoviral G5G8 would presumably lower plasma cholesterol levels in db/db mice. However, a significant portion of the secreted cholesterol was reabsorbed, resulting in a paradoxical increase in plasma cholesterol despite increased biliary output. This effect of adenoviral G5G8 can be overcome by coadministration of ezetimibe (EZ), a potent inhibitor of cholesterol absorption that blocks Niemann-Pick C1-like 1 (NPC1L1) activity in the intestine (7Su K. Sabeva N.S. Wang Y. Liu X. Lester J.D. Liu J. Liang S. Graf G.A. Acceleration of biliary cholesterol secretion restores glycemic control and alleviates hypertriglyceridemia in obese db/db mice.Arterioscler. Thromb. Vasc. Biol. 2014; 34: 26-33Crossref PubMed Scopus (16) Google Scholar, 8Davis Jr., H.R. Zhu L.J. Hoos L.M. Tetzloff G. Maguire M. Liu J. Yao X. Iyer S.P. Lam M.H. Lund E.G. et al.Niemann-Pick C1 Like 1 (NPC1L1) is the intestinal phytosterol and cholesterol transporter and a key modulator of whole-body cholesterol homeostasis.J. Biol. Chem. 2004; 279: 33586-33592Abstract Full Text Full Text PDF PubMed Scopus (591) Google Scholar). Similar observations were made in atherosclerosis studies in which a G5G8 transgene expressed in both liver and intestine lowered LDL cholesterol and reduced lesion area, whereas a liver specific transgene was ineffective in the absence of EZ (9Wilund K.R. Yu L. Xu F. Hobbs H.H. Cohen J.C. High-level expression of ABCG5 and ABCG8 attenuates diet-induced hypercholesterolemia and atherosclerosis in Ldlr−/− mice.J. Lipid Res. 2004; 45: 1429-1436Abstract Full Text Full Text PDF PubMed Scopus (75) Google Scholar, 10Basso F. Freeman L.A. Ko C. Joyce C. Amar M.J. Shamburek R.D. Tansey T. Thomas F. Wu J. Paigen B. et al.Hepatic ABCG5/G8 overexpression reduces apoB-lipoproteins and atherosclerosis when cholesterol absorption is inhibited.J. Lipid Res. 2007; 48: 114-126Abstract Full Text Full Text PDF PubMed Scopus (53) Google Scholar). These observations indicate an interdependent relationship between biliary secretion and intestinal absorption for effective fecal cholesterol elimination. Consequently, therapeutic approaches to promote cholesterol elimination by targeting the hepatobiliary pathway are likely to be limited by intestinal reabsorption of secreted cholesterol. Thus, a combination therapy that increases biliary cholesterol secretion and simultaneously reduces intestinal absorption is likely to act additively in the elimination of cholesterol from the body. While EZ is effective in reducing cholesterol absorption, no currently available therapeutics directly target the G5G8 sterol transporter to increase biliary cholesterol secretion. However, we previously published that tauroursodeoxycholic acid (TUDCA) increases G5G8 and biliary cholesterol in both lean and obese, db/db mice (11Sabeva N.S. Rouse E.J. Graf G.A. in the reduce of the sterol transporter in Biol. Chem. 2007; Full Text Full Text PDF PubMed Scopus Google Scholar). is a of ursodiol in mice have that and its have a of effects liver of improved insulin and reduced (11Sabeva N.S. Rouse E.J. Graf G.A. in the reduce of the sterol transporter in Biol. Chem. 2007; Full Text Full Text PDF PubMed Scopus Google Scholar, T. M. T. K. S. acid insulin and hepatic steatosis by inducing the of hepatic in high-fat 2012; Full Text Full Text PDF PubMed Scopus Google Scholar, L. M. C.Z. reduce and in a mouse model of PubMed Scopus Google Scholar). However, the effect of Urso increasing G5G8 and biliary secretion of cholesterol not been In the we that Urso effects G5G8 Urso increased hepatic G5G8 and both biliary and fecal sterol excretion. We whether an Urso-EZ combination treatment would act additively to promote cholesterol elimination. We treated mice with a of Urso or Urso in combination with two doses of EZ. EZ produced an additive effect for fecal sterol in the presence of Urso. Although biliary and fecal neutral sterols were invariably lower in G5G8 KO mice, we an increase in FNS following Urso alone or Urso-EZ combination The of increase was not affected by that be a pathway for cholesterol elimination by Urso. were from from from was from Urso were from and (EZ) from and and the were from The and the were previously reported (6Su K. Sabeva N.S. Liu J. Wang Y. Bhatnagar S. van der Westhuyzen D.R. Graf G.A. The ABCG5 ABCG8 sterol transporter opposes the development of fatty liver disease and loss of glycemic control independently of phytosterol accumulation.J. Biol. Chem. 2012; 287: 28564-28575Abstract Full Text Full Text PDF PubMed Scopus (40) Google Scholar, G.A. Yu L. R. Cohen J.C. Hobbs H.H. ABCG5 and ABCG8 are for protein and biliary cholesterol Biol. Chem. Full Text Full Text PDF PubMed Scopus Google Scholar). The was from and were from of van L. Liu X. et of in plasma and 2011; PubMed Scopus Google Scholar). The was protein was from diet was from and were from and sterol were previously (6Su K. Sabeva N.S. Liu J. Wang Y. Bhatnagar S. van der Westhuyzen D.R. Graf G.A. The ABCG5 ABCG8 sterol transporter opposes the development of fatty liver disease and loss of glycemic control independently of phytosterol accumulation.J. Biol. Chem. 2012; 287: 28564-28575Abstract Full Text Full Text PDF PubMed Scopus (40) Google Scholar). was no cholesterol in the Urso and EZ were a and with control diet or to the were to mice in and C57BL/6J mice were from The for the and and were from previously (6Su K. Sabeva N.S. Liu J. Wang Y. Bhatnagar S. van der Westhuyzen D.R. Graf G.A. The ABCG5 ABCG8 sterol transporter opposes the development of fatty liver disease and loss of glycemic control independently of phytosterol accumulation.J. Biol. Chem. 2012; 287: 28564-28575Abstract Full Text Full Text PDF PubMed Scopus (40) Google Scholar). were in in a with a and with in the of and were to diet for a of to of The diet was to of Urso and EZ. to for and of and were by the and the of was and were made to C57BL/6J mice were with or Urso of or for were in were in to for to the of the mice were to and for The was and the for body was a of 1 were and in and of C57BL/6J mice were with Urso or Urso with or EZ for and were and were G5G8 KO mice both and and and were between and a diet to the development of sitosterolemia (6Su K. Sabeva N.S. Liu J. Wang Y. Bhatnagar S. van der Westhuyzen D.R. Graf G.A. The ABCG5 ABCG8 sterol transporter opposes the development of fatty liver disease and loss of glycemic control independently of phytosterol accumulation.J. Biol. Chem. 2012; 287: 28564-28575Abstract Full Text Full Text PDF PubMed Scopus (40) Google Scholar). levels of are of in G5G8 KO mice diet and not between to of the mice were to a diet for mice were a control diet for by Urso for mice were treated with Urso with EZ for were the of were by the of following and were of and G5G8 KO and mice for and treated with Urso or a control diet for were used to both cholesterol absorption and intestinal with L. K. Hobbs H.H. Cohen J.C. in mice ABCG5 and Lipid Res. Full Text Full Text PDF PubMed Scopus Google Scholar, L.J. C. intestinal a of PubMed Scopus Google Scholar). were and to a diet for to the in mouse was with of in the in the were for To determine the relative of intestinal and mouse was with 1 were and of the small intestine were and in neutral for are available in the The of and were previously (6Su K. Sabeva N.S. Liu J. Wang Y. Bhatnagar S. van der Westhuyzen D.R. Graf G.A. The ABCG5 ABCG8 sterol transporter opposes the development of fatty liver disease and loss of glycemic control independently of phytosterol accumulation.J. Biol. Chem. 2012; 287: 28564-28575Abstract Full Text Full Text PDF PubMed Scopus (40) Google Scholar, K. Sabeva N.S. Wang Y. Liu X. Lester J.D. Liu J. Liang S. Graf G.A. Acceleration of biliary cholesterol secretion restores glycemic control and alleviates hypertriglyceridemia in obese db/db mice.Arterioscler. Thromb. Vasc. Biol. 2014; 34: 26-33Crossref PubMed Scopus (16) Google Scholar). were from liver the and to with To determine relative was (6Su K. Sabeva N.S. Liu J. Wang Y. Bhatnagar S. van der Westhuyzen D.R. Graf G.A. The ABCG5 ABCG8 sterol transporter opposes the development of fatty liver disease and loss of glycemic control independently of phytosterol accumulation.J. Biol. Chem. 2012; 287: 28564-28575Abstract Full Text Full Text PDF PubMed Scopus (40) Google Scholar). Hepatic were by previously (7Su K. Sabeva N.S. Wang Y. Liu X. Lester J.D. Liu J. Liang S. Graf G.A. Acceleration of biliary cholesterol secretion restores glycemic control and alleviates hypertriglyceridemia in obese db/db mice.Arterioscler. Thromb. Vasc. Biol. 2014; 34: 26-33Crossref PubMed Scopus (16) Google Scholar). and hepatic and cholesterol and in were The of in was by previously P. of PubMed Google Scholar). was by and were for cholesterol previously (6Su K. Sabeva N.S. Liu J. Wang Y. Bhatnagar S. van der Westhuyzen D.R. Graf G.A. The ABCG5 ABCG8 sterol transporter opposes the development of fatty liver disease and loss of glycemic control independently of phytosterol accumulation.J. Biol. Chem. 2012; 287: 28564-28575Abstract Full Text Full Text PDF PubMed Scopus (40) Google Scholar). The of and in were by and respectively, of previously published L. J. K. Cohen J.C. Hobbs H.H. of and in mice role in biliary cholesterol PubMed Scopus Google Scholar, J. Cohen J.C. Hobbs H.H. of in liver and Lipid Res. Full Text Full Text PDF PubMed Scopus Google Scholar, for and of sterols and from human Lipid Res. 2012; Full Text Full Text PDF PubMed Scopus Google Scholar, A. T. T. J. K. M. Y. and specific of sterol in by Biol. PubMed Scopus Google Scholar). are available in the were previously with (7Su K. Sabeva N.S. Wang Y. Liu X. Lester J.D. Liu J. Liang S. Graf G.A. Acceleration of biliary cholesterol secretion restores glycemic control and alleviates hypertriglyceridemia in obese db/db mice.Arterioscler. Thromb. Vasc. Biol. 2014; 34: 26-33Crossref PubMed Scopus (16) Google Scholar). from the were and to An of of was a with of and of were in a for and of was used the the was and in The of neutral sterols and was by were are expressed in were by or by in were by by in were by a or a and treatment were made were significant and treatment by were not were independent of no effect cholesterol levels in liver or cholesterol in for Hepatic cholesterol of for The expression for cholesterol and and and was by for are between and control were by between control and doses of Urso were by by produced an additive effect for fecal sterol elimination. mice were with control, or Urso with a or of EZ for Hepatic levels of ABCG5 and ABCG8 protein expression were by cholesterol secretion for FNS was by for are were by by reduced free cholesterol in no additive effect the of and cholesterol in cholesterol and cholesterol were by were from the in and free cholesterol. for Hepatic cholesterol of for The expression for cholesterol and and and was by for are were by by reduced intestinal G5G8 and The expression for and was by for of and from mice in was by and for the of cholesterol for are were by by increase in FNS not G5G8 KO mice both and and were sequentially with control, and Urso EZ for and biliary cholesterol secretion by FNS and the relative in fecal sterol loss to of and KO and mice of and were a diet or Urso for The cholesterol absorption was by and of The relative of intestinal and were by were mice and the of in was are expressed were by by and a diet and by and by To determine whether Urso could increase G5G8 and biliary cholesterol secretion and elimination, mice were or with or Urso. to was used a control it was previously to increase G5G8 and biliary cholesterol secretion. The of hepatic and was by Urso increased hepatic G5G8 to a effects were or for cholesterol and FNS were used of G5G8 cholesterol secretion were from the of and cholesterol Urso increased both biliary cholesterol secretion and FNS Similarly, Urso increased biliary of both and in a dose-dependent Urso no effect or hepatic cholesterol of the doses To determine whether the increased FNS was due to increased cholesterol we the expression of and and no To the effects of Urso the expression of cholesterol sterol and sterol was by significantly both and not and Similarly, both and in a dose-dependent following Urso with Urso no effect and expression levels To determine whether EZ plays an additive role for cholesterol elimination, we treated mice with Urso with two doses of EZ for with Urso increased G5G8 protein levels in This effect was in the presence of both and doses of EZ The presence of EZ no effect biliary secretion of cholesterol and following of treatment However, EZ increased FNS in the presence of Urso EZ a of reduced cholesterol. This was due to the significant of free cholesterol were in hepatic free or cholesterol Although was a of cholesterol the We the of and the in mice treated with Urso. EZ no effect levels This effect of Urso is likely due to the of factor which to hepatic To determine whether to the increased FNS in to we the expression of and in and an of body cholesterol and van der is an of whole-body cholesterol in Lipid Res. Full Text PDF PubMed Google Scholar). Urso not the expression of and in However, the Urso-EZ combination increased expression in both and levels of to increase not studies cholesterol an for cholesterol elimination, the role of the intestine der van van H. R. K. F. of the liver of plasma Biol. Chem. 2009; Full Text Full Text PDF PubMed Scopus Google Scholar). G5G8 is also expressed the intestine to cholesterol and phytosterol we the expression of G5G8 both and protein levels intestinal which to intestinal J. C. B. et directly to in PubMed Scopus Google Scholar). Urso alone to decrease G5G8 the not However, a in G5G8 protein levels The combination of EZ further reduced G5G8 both and protein We not in the The combination of Urso and EZ also significantly intestinal both the and protein levels of a in cholesterol and a Thus, the in cholesterol is likely to reduced and To determine the extent to which the effect of Urso and Urso-EZ were G5G8 and KO mice were a control by Urso and Urso-EZ mouse its fecal and were the of treatment G5G8 KO mice lower invariably lower of biliary cholesterol secretion In the absence of were reduced by in G5G8 KO mice with Urso increased in both and G5G8 KO mice by and EZ produced a further increase in both Thus, were invariably lower in G5G8 KO mice, the increase were not in cholesterol contributing to FNS intestinal cholesterol absorption and was no cholesterol to the cholesterol absorption 90% in both and KO mice Urso reduced absorption in both This the role of G5G8 in cholesterol absorption or the of the cholesterol with increased biliary cholesterol output. were in and mice The effects of Urso intestinal and are not To effect in we a L.J. C. intestinal a of PubMed Scopus Google Scholar). was used a control by and increased In G5G8 to to Urso These indicate that cholesterol elimination is independent of The of the are that Urso increases G5G8 and that Urso-EZ acts in an additive to promote fecal sterol in mice. While G5G8 is the primary for biliary cholesterol secretion, studies a pathway for cholesterol elimination by Urso and Urso-EZ combination is to biliary or to be cholesterol secretion an essential of the cholesterol which the of cholesterol from to the liver for secretion and elimination in The plasma Lipid Res. Full Text PDF PubMed Google Scholar). long been a therapeutic in the treatment of atherosclerosis R. H. Wang X. Yao C. cholesterol and cholesterol in PubMed Scopus Google Scholar, cholesterol and atherosclerosis PubMed Scopus Google Scholar). However, the role of biliary cholesterol secretion in the development and of NAFLD is a We have published the G5G8 and biliary cholesterol secretion in the of NAFLD (6Su K. Sabeva N.S. Liu J. Wang Y. Bhatnagar S. van der Westhuyzen D.R. Graf G.A. The ABCG5 ABCG8 sterol transporter opposes the development of fatty liver disease and loss of glycemic control independently of phytosterol accumulation.J. Biol. Chem. 2012; 287: 28564-28575Abstract Full Text Full Text PDF PubMed Scopus (40) Google Scholar, K. Sabeva N.S. Wang Y. Liu X. Lester J.D. Liu J. Liang S. Graf G.A. Acceleration of biliary cholesterol secretion restores glycemic control and alleviates hypertriglyceridemia in obese db/db mice.Arterioscler. Thromb. Vasc. Biol. 2014; 34: 26-33Crossref PubMed Scopus (16) Google Scholar). Consequently, studies to have not biliary secretion a therapeutic in or in the treatment of NAFLD. Although G5G8 been to increase cholesterol for more a been in drug development for This is increasing biliary cholesterol secretion is to the cholesterol of and the risk for cholesterol However, Urso is a with and J.D. of by Lipid Res. 2009; Full Text Full Text PDF PubMed Scopus Google Scholar, P. of acid in with liver disease.Curr. PubMed Scopus Google Scholar). was used for cholesterol it reduces of the and increases two that increasing G5G8 with Urso to increase biliary cholesterol secretion in the absence of increased risk of be a therapeutic to of studies and have Urso or EZ in the treatment of NAFLD or with Urso were Urso reduced of inflammation to significantly NASH in two studies K.D. Kowdley K.V. E.J. R. P. L. P. acid for treatment of nonalcoholic of a 2004; PubMed Scopus Google Scholar, F. A. B. M. A. of acid with in nonalcoholic Full Text Full Text PDF PubMed Scopus Google Scholar). Urso to reduce or in in a Urso lowered levels by an of and and in of with no or in the F. P. C. C. P. M. L. et of acid for nonalcoholic 2011; Full Text Full Text PDF PubMed Scopus Google Scholar, L.A. P. J. J. K.D. of acid in nonalcoholic PubMed Scopus Google Scholar). Although the of studies and were EZ in the treatment of NAFLD. In a in EZ reduced plasma and hepatic of insulin resistance were M. K. Y. H. H. K. K. H. H. M. et of ezetimibe for the treatment of non-alcoholic an Res. PubMed Scopus Google Scholar). In the to in a EZ reduced and resulted in significant in and of NAFLD by H. T. K. H. M. K. Y. T. M. G. et of ezetimibe therapy in with nonalcoholic fatty liver 2011; PubMed Scopus Google Scholar). However, is currently in the treatment of NAFLD. The limited benefit be due to the interdependent of biliary secretion and intestinal absorption with to cholesterol elimination. a combination therapy that simultaneously increases biliary secretion and reduces cholesterol absorption therapeutic benefit with Urso or EZ was that Urso-EZ combination treatment would further fecal sterol loss and a sterol or In the the extent of cholesterol loss is directly by the of cholesterol In the no an increase in body cholesterol a increase in and In addition, an diet to a of hepatic and Thus, the increase in FNS of cholesterol from the G5G8 the of a cholesterol The by which Urso simultaneously increases G5G8 and is not be due to the of which acts factor in liver to M.J. and from to 2012; PubMed Scopus Google Scholar). also the protein in the effect of G5G8 is not M.J. and from to 2012; PubMed Scopus Google Scholar, S. P. K. Xu a of hepatic protein and 2011; PubMed Scopus Google Scholar). studies suggest that the is a for that is a for tauroursodeoxycholic 2013; 57: PubMed Scopus Google Scholar, H. B. A. R. are for tauroursodeoxycholic acid in 2013; 57: PubMed Scopus Google Scholar). However, the effect of G5G8 is not it whether the of and the of G5G8 in to Urso or independent the are be a therapeutic biliary cholesterol secretion could increase to a extent in to promote therapeutic approaches to increase G5G8 and biliary cholesterol secretion would to be in combination with EZ to However, an increase the risk of in studies was that Urso and Urso-EZ increased FNS in G5G8 KO mice in This could be to the which for of fecal sterol loss in mice and is an essential to the hepatobiliary pathway der van van H. R. K. F. of the liver of plasma Biol. Chem. 2009; Full Text Full Text PDF PubMed Scopus Google Scholar). We not simultaneously biliary and intestinal cholesterol secretion in we to extent biliary to the fecal sterol However, Urso and Urso-EZ in G5G8-deficient mice be in biliary and for cholesterol elimination. The and the of for with of and the of for with the for for with intestinal for and and for with with acid cholesterol sterol sterol ezetimibe factor fecal neutral sterol ABCG5 ABCG8 high-fat nonalcoholic fatty liver disease nonalcoholic steatohepatitis Niemann-Pick C1-like 1 plant sterol-free cholesterol cholesterol tauroursodeoxycholic acid ursodiol

References

33